NurExone Biologic: Expanding U.S. Presence and Awareness at Prestigious Conference

NurExone Biologic (TSXV: NRX) (OTCQB: NRXBF) continues to expand its U.S. presence and raise awareness within the biotech and investor communities by announcing its participation in the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting. The conference, taking place from May 7-10, 2025, in New Orleans, Louisiana, provides an ideal platform for NurExone to showcase its innovative ExoPTEN therapy and engage with leading experts in the field.

As part of its growth and awareness strategy, NurExone will present a session titled "ExoPTEN: Allogeneic Exosome Therapy for Spinal Cord Injury with Strong Therapeutic Potential and Clinical Promise." The presentation will highlight the company's robust preclinical data, demonstrating significant improvements in motor and sensory functions and structural recovery in small animal models of spinal cord injury following a minimally invasive ExoPTEN treatment cycle.

Dr. Tali Kizhner, Director of Research and Development at NurExone, emphasized the importance of presenting at high-profile U.S. conferences like ISCT 2025, stating, "We are honored to present this cutting-edge research to leading experts in the field and further establish our position as a pioneer in exosome-based regenerative therapies." This opportunity allows NurExone to increase its visibility within the North American biotech and investor communities.

Eran Ovadya, Chief Financial Officer of NurExone, highlighted the strategic significance of participating in prestigious events like ISCT 2025, noting, "The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S. listing opportunities, presenting at prestigious events is expected to strengthen our strategy and increase shareholder value."

The Company's presence at ISCT 2025 underscores its commitment to advancing its innovative therapies globally. Recently, NurExone launched its U.S. subsidiary, Exo-Top Inc. ("Exo-Top"), which focuses on the production and supply of high-quality, fully characterized good manufacturing practice ("GMP") exosomes for research and therapeutic use. The exosomes produced will be used for NurExone's product development as well as for supply to third parties, further expanding the Company's footprint in the U.S. market.

In conclusion, NurExone's participation in the ISCT 2025 Annual Meeting aligns with its U.S. expansion strategy, providing an opportunity to showcase its innovative therapies, engage with leading experts, and increase its visibility within the North American biotech and investor communities. The establishment of Exo-Top Inc. further strengthens NurExone's position in the U.S. market, contributing to its growth and market position both domestically and globally.